Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line.

MLA

Rivoltini, Licia, et al. “Modulation of Multidrug Resistance by Verapamil or Mdr1 Anti-Sense Oligodeoxynucleotide Does Not Change the High Susceptibility to Lymphokine-Activated Killers in Mdr-Resistant Human Carcinoma (LoVo) Line.” International Journal of Cancer, vol. 46, no. 4, Oct. 1990, pp. 727–32. EBSCOhost, https://doi.org/10.1002/ijc.2910460429.

APA

Rivoltini, L., Colombo, M. P., Supino, R., Ballinari, D., Tsuruo, T., & Parmiani, G. (1990). Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. International Journal of Cancer, 46(4), 727–732. https://doi.org/10.1002/ijc.2910460429

Chicago

Rivoltini, Licia, Mario P. Colombo, Rosanna Supino, Dario Ballinari, Takashi Tsuruo, and Giorgio Parmiani. 1990. “Modulation of Multidrug Resistance by Verapamil or Mdr1 Anti-Sense Oligodeoxynucleotide Does Not Change the High Susceptibility to Lymphokine-Activated Killers in Mdr-Resistant Human Carcinoma (LoVo) Line.” International Journal of Cancer 46 (4): 727–32. doi:10.1002/ijc.2910460429.